NCT01634685已完成1 期
A Phase I Study of the Phosphatidylserine-Targeting Antibody Bavituximab in Combination With Capecitabine and Radiation Therapy for the Treatment of Stage II and III Rectal Adenocarcinoma
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 15
- 试验地点
- 1
- 主要终点
- dose-limiting toxicities (DLT)
研究概览
简要总结
This is a phase I study incorporating bavituximab into the care of patients with rectal adenocarcinoma simultaneously treated with capecitabine and radiation therapy. There is no reference therapy as we are trying to identify the MTD of bavituximab in this combination.
详细描述
The investigational drug in this protocol is bavituximab, which will be delivered concurrently with the radiation therapy for 6 weeks (one time each week), followed by 2 weeks of bavituximab administration by itself. If the other therapies are terminated after week 4 the bavituximab treatment may be continued per protocol. A chemotherapy agent, capecitabine, will be delivered twice daily p.o. on the days of radiation treatment, at a dose of 825 mg/m2. Radiation therapy will be administered daily, Monday-Friday, for a total of 28 treatments, delivered at 1.8 Gy/fraction. Surgery will follow the last bavituximab administration by 4-8 weeks (6-10 weeks following completion of radiation therapy.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 99 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Biopsy-proven invasive adenocarcinoma of the rectum, stage T3-4 and/or node-positive (AJCC stage II or III). For the purpose of this study, a tumor is located in the "rectum" when its distal edge is located within 12cm of the anal verge. The distal edge of the tumor can be delineated by digital examination or endoscopic examination, including colonoscopy, although rigid proctoscopy is preferred.
- •Age > 18 years.
- •Performance status of 0 or 1 on the ECOG scale is required (See Appendix 1).
- •Adequate organ and marrow function as defined below:
- •leukocytes ≥ 3,000/mcL
- •absolute neutrophil count ≥ 1,500/mcL
- •platelets ≥ 100,000/mcl
- •total bilirubin within normal institutional limits
- •AST(SGOT)/ALT(SGPT) ≤ 2.5 X institutional upper limit of normal
- •creatinine <1.5 X institutional upper limits of normal
- •aPTT ≤1.5 X institutional upper limits of normal
- •Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation, and for 90 days following completion of therapy. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately.
- •A female of child-bearing potential is any woman (regardless of sexual orientation, having undergone a tubal ligation, or remaining celibate by choice) who meets the following criteria:
- •Has not undergone a hysterectomy or bilateral oophorectomy;
- •or has not been naturally postmenopausal for at least 12 consecutive months (i.e., has had menses at any time in the preceding 12 consecutive months).
- •Ability to understand and the willingness to sign a written informed consent
排除标准
- •Known history of bleeding diathesis or coagulopathy (e.g., von Willebrand disease or hemophilia).
- •Clinically significant bleeding, such as gross hematuria, gastrointestinal bleeding (excluding bleeding from rectal tumor), and hemoptysis within the 12 months before screening. If clinically significant bleeding has occurred within 12 months of screening but the cause has been identified and adequately treated (e.g., cystitis, ulcer), then this exclusion criterion does not apply.
- •Minor biopsy-related bleeding lasting < 24 hours and resolved at least 1 week before Study Day 1 is allowed.
- •Venous thromboembolic events (e.g., deep vein thrombosis or pulmonary embolism) within 6 months of screening.
- •Ongoing therapy with oral or parenteral anticoagulants; low-dose anticoagulation to maintain patency of lines is allowed.
- •Concurrent estrogens, anti-estrogens or progesterone compounds.
- •Any prior radiation for rectal cancer.
- •Symptomatic or clinically active brain metastases.
- •Major surgery within 4 weeks of Study Day
- •Pregnant or nursing women.
- •Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, history of blood clotting abnormalities, or psychiatric illness/social situations that would limit compliance with study requirements.
- •Symptomatic coronary artery disease, cerebrovascular accident, transient ischemic attack, myocardial infarction, or unstable angina pectoris within 6 months of screening.
- •Known chronic infection with human immunodeficiency virus (HIV) or viral hepatitis.
- •Known hypersensitivity to any components of the treatments.
- •History of malignancy other than non-melanoma skin cancers within 5 years prior to study enrollment.
- •Subjects receiving other investigational agents thirty days prior to study treatment or during treatment.
- •History of inflammatory bowel disease
研究组 & 干预措施
Bavituximab, Capecitabine, Radiation
Experimental
one arm
干预措施: Capecitabine (Drug)
Bavituximab, Capecitabine, Radiation
Experimental
one arm
干预措施: Radiation (Radiation)
Bavituximab, Capecitabine, Radiation
Experimental
one arm
干预措施: Bavituximab (Drug)
结局指标
主要结局
dose-limiting toxicities (DLT)
时间窗: 28 days
To determine dose-limiting toxicities (DLT) for bavituximab when administered on a weekly basis concurrently with external beam radiation therapy.
次要结局
- adverse events(12 weeks)
- MR imaging and histopathological response(12 weeks)
- tumor-vasculature parameters(week 3 and 12)
- maximally tolerated dose (MTD)(28 days)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
Study of Bavituximab in Patients With Chronic Hepatitis C Virus InfectionHepatitis CNCT00128271Peregrine Pharmaceuticals32
撤回
1 期
Therapy for Progressive and/or Refractory Hematologic MalignanciesHematologic MalignanciesCancerNCT02223312Kiromic BioPharma Inc.
撤回
1 期
Consolidation Therapy in Patients With Hematologic MalignanciesHematologic MalignanciesCancerNCT02709993Kiromic BioPharma Inc.
已完成
1 期
Phase I Study of PI3(Phosphoinositol 3)-Kinase Inhibitor BAY80-6946 With Paclitaxel in Patients With Advanced CancerNeoplasmsNCT01411410Bayer55
撤回
2 期
A Study of Neoadjuvant Paclitaxel in Combination With Bavituximab in Early- Stage Triple- Negative Breast CancerTriple Negative Breast NeoplasmsTriple-Negative Breast NeoplasmBreast CancerTriple Negative Breast CancerER-Negative PR-Negative HER2-Negative Breast NeoplasmsER-Negative PR-Negative HER2-Negative Breast CancerTriple-Negative Breast CancerNCT02685306Peregrine Pharmaceuticals